Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Big Books & Bold Ideas with Kerri Miller
Kerri Miller and Marcheta Fornoff

Researchers are making progress on a COVID-19 vaccine, but the race isn’t over yet

Researchers are making progress on a COVID-19 vaccine, but the race isn’t over yet

A subject receives a shot
A subject receives a shot in the first-stage safety study clinical trial of a potential vaccine by Moderna for COVID-19 at the Kaiser Permanente Washington Health Research Institute in Seattle on March 16, 2020. According to results released on Tuesday, July 14, 2020, early-stage testing showed the first COVID-19 vaccine tested in the U.S. revved up people's immune systems the way scientists had hoped. The vaccine is made by the National Institutes of Health and Moderna Inc.
Ted S. Warren | AP Photo file

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

Initial results from three separate groups working on COVID-19 vaccines look promising, but that doesn’t mean doses will be available at a local pharmacy soon.

Even if a formula gets approved, being able to manufacture and distribute enough doses at a global scale will be challenging.

Getting community buy-in is another hurdle. Polling from May showed that roughly half of Americans would get a COVID-19 vaccine if it was available. A separate poll from June found that around 7 in 10 Americans were willing to get the vaccine.

On Wednesday at 9 a.m., two experts joined MPR News host Kerri Miller for a conversation about the race to develop a COVID-19 vaccine. 

Guests: 

To listen to the full conversation you can use the audio player above.


Subscribe to the MPR News with Kerri Miller podcast on: Apple Podcasts, Google Podcasts , Spotify or RSS